enestnd: results from an exploratory biomarker analysis in cml
Published 4 years ago • 91 plays • Length 3:59Download video MP4
Download video MP3
Similar videos
-
1:37
long-term follow-up from a phase ii trial of olutasidenib in idh1-mutated aml
-
2:18
analysis of real-world outcomes in patients with b-all receiving tisagenlecleucel
-
2:12
results from phase i study of alnuctamab administered intravenously & subcutaneously in r/r myeloma
-
1:03
an insight into the sequencing of immunotherapies in adults with all
-
3:26
informcll: a prospective observational registry
-
1:42
immune profiling & mrd negativity of ndmm treated with quadruplet induction autosct: milestone trial
-
1:02
a phase ii single-arm study of obinutuzumab plus ibrutinib as frontline treatment for fl and mzl
-
1:26
phase i trial of copanlisib nivolumab in patients with richter’s transformation or transformed fl
-
4:58
findings of a phase i study of anitocabtagene autoleucel for the treatment of r/r myeloma
-
27:52
cell profiling and biomarker discovery in a spatial context [webinar]
-
4:06
a phase ii trial of intermittent treatment strategies for ndmm to avoid asct
-
2:47
using artificial intelligence to estimate overall mortality and non-relapse mortality after allosct
-
1:07
key advancements in the treatment of bpdcn from ebmt 2024
-
4:48
an insight into the management of cytopenias in mf
-
2:00
real-world bortezomib prescribing patterns and outcomes in ndmm
-
1:54
nivolumab ibrutinib for patients with richter’s transformation
-
1:28
phase i study of pevonedistat and ibrutinib in r/r b-nhl
-
2:32
ongoing trials in amyloidosis
-
0:52
extended follow-up of ambassador: adjuvant pembrolizumab in miuc
-
1:34
future of real world evidence | the way we see it
-
2:38
unmet needs in imaging for the diagnosis of al amyloidosis
-
6:05
real-world data on the effect of ibrutinib flexible dosing treatment strategies on ttnt in cll/sll